title: Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertension.
abstract: The use of multiple drug regimens is increasingly recognized as a tacit requirement for the management of hypertension, a necessity fueled in part by rising rates of metabolic syndrome and diabetes. By targeting complementary pathways, combinations of antihypertensive drugs can be applied to provide effective blood pressure control while minimizing side effects and reducing exposure to high doses of individual medications. In addition, combination therapies, including angiotensin converting enzyme (ACE) inhibitors and calcium channel blockers (CCBs), have the added benefit of reducing cardiovascular mortality and morbidity over other dual therapies while providing equivalent blood pressure control. It is possible that angiotensin receptor blockers (ARBs), which unlike ACE inhibitors are minimally affected by upregulation of alternative pathways for angiotensin II accumulation following long-term treatment, would also provide such outcome benefits. At issue, however, is maintaining patient compliance, as adding medications is known to reduce adherence to treatment regimens. The purpose of this review is to summarize existing trial data for the long-term safety and efficacy of a recent addition to the armamentarium of dual-antihypertensive therapeutic options, the telmisartan/amlodipine single pill combination. The areas where long-term data are lacking, notably clinical information regarding minorities and women, will also be discussed.
authors: Beaumont Health System, Ministrelli Women's Heart Center, Royal Oak, MI 48073, USA. ssbillecke@gmail.com
authors: Scott S
authors: SS
authors: Billecke
authors: Pamela A
authors: PA
authors: Marcovitz
mesh_terms: D017311:Amlodipine / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001565:Benzoates / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects*; D002121:Calcium Channel Blockers / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D018579:Patient Selection; D012307:Risk Factors; D000077333:Telmisartan; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D002121:Calcium Channel Blockers; D004338:Drug Combinations; C548840:telmisartan amlodipine combination; D017311:Amlodipine; D000077333:Telmisartan
keywords: Angiotensin receptor blocker; antihypertensive; calcium channel blocker; clinical trial; combination pill
references: J Int Med Res. 2000 Jul-Aug;28(4):149-67
references: 11014323
references: Drugs. 2002;62(3):443-62
references: 11827559
references: J Manag Care Pharm. 2007 Oct;13(8 Suppl B):9-20
references: 17970613
references: Arch Intern Med. 2007 Sep 10;167(16):1798-803
references: 17846400
references: Nephrology (Carlton). 2006 Oct;11(5):462-6
references: 17014562
references: Am Fam Physician. 2005 Jun 1;71(11):2089-90
references: 15952435
references: J Hum Hypertens. 2011 Apr;25(4):271-7
references: 20445570
references: Clin Ther. 2012 Mar;34(3):537-51
references: 22386829
references: J Hum Hypertens. 2007 Dec;21(12):914-6
references: 17700727
references: J Int Med Res. 2009 Nov-Dec;37(6):1662-79
references: 20146864
references: Blood Press Monit. 2010 Aug;15(4):205-12
references: 20613496
references: Circ Res. 2007 Aug 31;101(5):455-64
references: 17626897
references: Am J Cardiol. 1999 Nov 18;84(10A):3S-8S
references: 10588088
references: Am J Cardiovasc Drugs. 2008;8(1):45-50
references: 18303937
references: J Clin Hypertens (Greenwich). 2010 Jun;12(6):414-21
references: 20591086
references: JAMA. 2003 May 14;289(18):2363-9
references: 12746359
references: Drugs. 1997 Dec;54(6):797-800
references: 9421690
references: Curr Ther Res Clin Exp. 2012 Feb;73(1-2):65-84
references: 24653513
references: Circ Cardiovasc Qual Outcomes. 2010 Mar;3(2):135-42
references: 20160159
references: Am J Med. 2009 Mar;122(3):290-300
references: 19272490
references: Expert Opin Pharmacother. 2011 Nov;12(16):2441-8
references: 21958068
references: Adv Ther. 2012 Jul;29(7):635-44
references: 22821644
references: J Hypertens. 2002 Nov;20(11):2099-110
references: 12409940
references: Clin Ther. 2001 Aug;23(8):1296-310
references: 11558866
references: Int J Clin Pract. 2009 May;63(5):766-75
references: 19392925
references: Med Care. 2005 Jun;43(6):521-30
references: 15908846
references: Circulation. 2012 Jan 3;125(1):e2-e220
references: 22179539
references: Expert Opin Pharmacother. 2011 Jun;12(9):1351-8
references: 21510830
references: J Clin Hypertens (Greenwich). 2011 Jul;13(7):459-66
references: 21762357
references: J Clin Pharmacol. 2000 Dec;40(12 Pt 1):1347-54
references: 11185633
references: Clin Cardiol. 2003 Feb;26(2 Suppl 2):II12-6
references: 12622321
references: Hypertension. 1992 Jun;19(6 Pt 2):692-6
references: 1317352
references: Circulation. 2007 Mar 20;115(11):1481-501
references: 17309915
references: J Clin Hypertens (Greenwich). 2009 Apr;11(4):207-13
references: 19614805
references: Int J Clin Pract. 2012 Aug;66(8):792-799
references: 22805271
references: Curr Med Res Opin. 2010 Sep;26(9):2065-76
references: 20629600
references: J Hypertens. 2007 Jun;25(6):1105-87
references: 17563527
references: Drugs. 2007;67(9):1309-27
references: 17547473
references: J Clin Hypertens (Greenwich). 2011 Sep;13(9):687-9
references: 21896151
references: J Hypertens. 2002 Aug;20(8):1461-4
references: 12172300
references: Hypertension. 1998 Jan;31(1 Pt 2):356-61
references: 9453328
references: J Clin Pharmacol. 2000 Dec;40(12 Pt 1):1312-22
references: 11185629
references: Hypertension. 1982 Mar-Apr;4(2):178-84
references: 6175571
references: Br J Clin Pharmacol. 1986;21 Suppl 2:109S-121S
references: 3530295
references: Circulation. 2011 Mar 1;123(8):933-44
references: 21262990
references: Cardiovasc Diabetol. 2009 Mar 27;8:18
references: 19327149
references: Hypertension. 2010 Feb;55(2):399-407
references: 20026768
references: Arch Intern Med. 2005 May 23;165(10):1147-52
references: 15911728
references: Lancet. 2005 Sep 10-16;366(9489):895-906
references: 16154016
references: Curr Hypertens Rep. 2005 Aug;7(4):240-3
references: 16061040
references: Clin Ther. 2012 Jul;34(7):1625-35
references: 22721873
references: Circulation. 2006 Mar 14;113(10):1353-60
references: 16520412
references: Exp Biol Med (Maywood). 2008 Aug;233(8):1035-43
references: 18480420
references: JAMA. 2010 May 26;303(20):2043-50
references: 20501926
references: JAMA. 2003 May 21;289(19):2560-72
references: 12748199
references: Oxid Med Cell Longev. 2010 Sep-Oct;3(5):342-6
references: 21150340
references: Dis Mon. 2005 Oct-Nov;51(10-11):548-614
references: 16360376
references: JAMA. 2005 Jul 27;294(4):466-72
references: 16046653
references: Vasc Health Risk Manag. 2008;4(5):971-81
references: 19183745
references: J Clin Hypertens (Greenwich). 2010 Jan;12(1):40-6
references: 20047629
references: J Hypertens. 2008 Apr;26(4):819-24
references: 18327094
references: Am J Cardiovasc Drugs. 2006;6(2):103-13
references: 16555863
references: Life Sci. 2012 Feb 13;90(7-8):289-300
references: 22210452
references: Am J Med. 2007 Aug;120(8):713-9
references: 17679131
references: Clin Pharmacokinet. 1992 Jan;22(1):22-31
references: 1532771
references: J Renin Angiotensin Aldosterone Syst. 2011 Mar;12(1):1-7
references: 20603272
references: Int J Clin Pract. 2009 May;63(5):790-8
references: 19220523
references: Pharmacol Rev. 2000 Sep;52(3):415-72
references: 10977869
references: Expert Opin Pharmacother. 2007 Apr;8(5):529-35
references: 17376010
references: Hypertension. 1999 Sep;34(3):457-60
references: 10489393
references: Am J Hypertens. 2007 Apr;20(4):417-22
references: 17386350
references: Int J Hypertens. 2012;2012:147825
references: 22319643
references: Postgrad Med. 2009 Mar;121(2):5-14
references: 19332958
references: Blood Press Monit. 2004 Aug;9(4):203-10
references: 15311147
references: Am J Physiol Heart Circ Physiol. 2007 Aug;293(2):H939-48
references: 17483239
references: Cardiovasc Diabetol. 2012 Apr 10;11:32
references: 22490507
references: Am J Cardiovasc Drugs. 2012 Apr 1;12(2):137-42
references: 22329591
references: J Clin Hypertens (Greenwich). 2004 Feb;6(2):76-84
references: 14872145
references: Exp Physiol. 2008 May;93(5):519-27
references: 18310257
references: Can J Cardiol. 2000 Sep;16(9):1123-32
references: 11021956
references: Int J Clin Pharmacol Res. 2005;25(1):41-6
references: 15864875
references: J Hypertens. 1991 Jul;9(7):631-8
references: 1653799
references: N Engl J Med. 2008 Dec 4;359(23):2417-28
references: 19052124
references: P T. 2008 Nov;33(11):652-66
references: 19750061